Ripple Mapping Guided Ablation of Ischaemic Ventricular Tachycardia.
Launched by IMPERIAL COLLEGE HEALTHCARE NHS TRUST · Jun 24, 2019
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
Patients who have ischaemic heart disease and are at sufficient risk of, or have suffered, ventricular tachycardia may receive implantable cardioverter defibrillator (ICD) devices. ICD devices provide life-saving shocks to terminate ventricular tachycardia. There is however substantial evidence that correlates each life-saving shock with worsening prognosis.
Catheter ablation is a procedure that can treat the cause of ischaemic ventricular tachycardia (VT). Most catheter ablation procedures for ischaemic VT are performed in normal rhythm, with an end-point of arrhythmic substrate modificat...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients with coronary artery disease and ischaemic cardiomyopathy requiring ICD implantation for primary or secondary prevention.
- • 2. Any episode of VT detected or treated appropriately (within monitor zone or therapy (ATP/shock) delivered) or by 12 lead ECG if the rate below the detection level of the device. An episode of VT will be defined as lasting more than 30 secs or a regular high rate episode meeting VT criterion for \>50% of the time before the first therapy is delivered (i.e. VT degenerating into VF is acceptable under these circumstances).
- • 3. Ablation or medical therapy would be considered reasonable option for ongoing management.
- • 4. Males or females 18 - 80 years of age.
- • 5. Suitable candidate for catheter ablation.
- • 6. Signed informed consent.
- Exclusion Criteria:
- • 1. Contraindication to catheter ablation.
- • 2. VT due to reversible causes.
- • 3. Severe valvular disease or ventricular thrombus.
- • 4. Active gastrointestinal bleeding.
- • 5. Serum Creatinine \>200μmol/L or on dialysis.
- • 6. Active fever or infection.
- • 7. Life expectancy shorter than the duration of the trial.
- • 8. Allergy to contrast.
- • 9. Intractable heart failure (NYHA Class IV).
- • 10. Bleeding or clotting disorders or inability to receive heparin.
- • 11. Malignancy needing surgery, chemotherapy or radiotherapy.
- • 12. Pregnancy or women of child-bearing potential not using a highly effective method of contraception.
- • 13. Unable to attend follow-up visits or ICD clinics.
About Imperial College Healthcare Nhs Trust
Imperial College Healthcare NHS Trust is a leading healthcare provider in London, renowned for its commitment to delivering high-quality patient care and advancing medical research. As an integral part of the NHS, the Trust encompasses a range of specialized services and facilities, including multiple hospitals and outpatient centers, where it fosters a collaborative environment for clinical trials. With a focus on innovation and excellence, Imperial College Healthcare NHS Trust supports a diverse portfolio of clinical research initiatives aimed at translating scientific discoveries into effective treatments and improving health outcomes for patients. Its partnership with Imperial College London enhances its capabilities in cutting-edge research, making it a pivotal institution in the landscape of healthcare and clinical trials.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Patients applied
Trial Officials
Prapa Kanagaratnam
Principal Investigator
Imperial College Healthcare NHS Trust
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials